<p>Metastatic Breast Cancer:</p>

<ul>
	<li>The most common adverse reactions (&gt; 30%) with Pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia,neutropenia, nausea, fatigue, rash, and peripheral neuropathy.</li>
</ul>

<p>Neoadjuvant Treatment of Breast Cancer:</p>

<ul>
	<li>The most common adverse reactions (&gt; 30%) with Pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia.</li>
	<li>The most common adverse reactions (&gt;30%) with Pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of FEC were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia.&nbsp;</li>
	<li>The most common adverse reactions (&gt;30%) with Pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (TCH) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia.</li>
	<li>The most common adverse reactions (&gt;30%) with Pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddAC were nausea, diarrhea, alopecia, fatigue, constipation and headache.</li>
	<li>The most common adverse reactions (&gt;30%) with Pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of FEC were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia.</li>
</ul>

<p>Adjuvant Treatment of Breast Cancer:</p>

<ul>
	<li>The most common adverse reactions (&gt;30%) with Pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy and vomiting.</li>
</ul>